SPRIG Consulting, LLC, is led by Katie Arnold, a strategic marketing professional with 20 years of health-care experience. Katie has worked with medical technology companies ranging from venture-backed startups to Fortune 500 companies. Throughout her career, Katie has focused on the entire spectrum of commercialization needs: from upstream market development strategies to downstream launch execution.
Prior to founding SPRIG, Katie was an independent marketing consultant working on projects that ranged from business plan refinement and market opportunity assessments to development of marketing strategies that included corporate/product positioning and brand development. Katie has demonstrated an aptitude for delivering flawless launch execution and commercialization strategy implementation in the U.S., EU and AP geographies. During her tenure, Katie is proud to have named numerous medical companies, products and technologies.
Prior to consulting, Katie had a successful career with Guidant Corporation (acquired) and Kensey Nash Corporation (acquired) launching new, novel technologies, such as thrombus management catheters, embolic protection devices and coronary stents. As Director of Marketing at Kensey Nash, Katie played a key role in establishing the company in the Endovascular space through a strategic corporate branding initiative and numerous product launches. At the end of her tenure, the division was sold to Spectranetics (SPNC). While at Guidant, Katie served as a Senior Global Product Manager and successfully led the launch of the company's first cobalt chromium stent for small vessels, the ML MINI VISION. Katie also held positions in strategic corporate marketing as well as sales.
Katie holds an MBA from Northwestern University's Kellogg School of Management, where she was awarded the Health Industry Management Scholarship for recognition of her leadership in the health industry. Currently, Katie is a Kellogg lecturer and teaches the course Medical Product Commercialization to future health-care leaders.
Prior to business school, Katie spent six years working in health-care risk management for the medical malpractice divisions of CNA Insurance Companies and MMI Insurance Company. In her role, Katie worked directly with physicians, hospital administrators, health-care systems and managed-care organizations. Katie holds a BA from the University of Vermont.
MBA, 2002, Marketing, Health Industry Management, and Biotechnology, Kellogg School of Management, Northwestern University
BA, 1994, Environmental Studies, University of Vermont
Founder and Principal Consultant, Sprig Consulting, LLC, 2008-present
Director of Market Development, Kensey Nash Corporation, 2005-2008
Senior Global Product Manager, Vascular Intervention, Guidant Corporation, 2001-2005
Medical Technology Financing and Commercialization (HCAK-611-0) This course offers students an experiential learning opportunity to work directly in the commercialization and fundraising process for innovative, pre-commercial medical technologies, to include devices, diagnostics, services and software solutions. The insights from this hands-on course will be most beneficial to students with an interest in entrepreneurship, start-ups, product design, early stage financing and product marketing.
Students will be placed on three-to-four member teams based on their skills, experience and project interests. Each team will function as members of the executive team working with select Northwestern tech transfer companies curated by Northwestern's INVO (Innovation and New Ventures Office). Each company will present their technology on the first day of class, after which students will rank their top choices and will be matched by the faculty to meet top preferences. Once matched, students will work with their respective companies to build a complete investor deck that will be delivered to a panel of industry and finance experts at the end of the quarter. Each class includes a faculty lecture and guest lecture in an effort to bring real world experiences and perspectives to each topic. Since its inception, this course has produced companies that competed in and won prestigious business plan competitions. It has also graduated several technologies/companies that are now FDA cleared and commercially available.
Note: This course may not be dropped after the first week of the quarter.